Skip to content

Henry Schein

US · HSIC #1526 by market cap Listed 1970
83.52 -1.28 -1.51%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:01

Recent news

  • Rating change
    Analysts Conflicted on These Healthcare Names: Henry Schein (HSIC), Arcus Biosciences (RCUS) and Incyte (INCY)
    TipRanks · 2026/10/21
  • Rating change
    Henry Schein Price Target Raised to $95.00/Share From $94.00 by UBS
    Dow Jones · 2026/11/5
  • Company notice
    Henry Schein | 3: Initial statement of beneficial ownership of securities- Caprais Emmanuel
    SEC · 2026/11/7
  • Company notice
    Henry Schein | SCHEDULE 13G/A: Others
    SEC · 2026/11/12
  • Rating change
    Barrington Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $104
    Market Newswire · 2026/10/21
  • A Quick Look at Today's Ratings for Henry Schein(HSIC.US), With a Forecast Between $85 to $110
    Market Newswire · 2026/11/5
  • Rating change
    Leerink Partners Maintains Henry Schein(HSIC.US) With Hold Rating, Announces Target Price $92
    Market Newswire · 2026/10/14
  • Rating change
    Baird Adjusts Henry Schein Price Target to $107 From $109
    MT Newswires · 2026/10/15
  • Rating change
    Henry Schein Price Target Cut to $100.00/Share From $105.00 by Evercore ISI Group
    Dow Jones · 2026/11/4
  • Company notice
    Henry Schein | 10-Q: Quarterly report
    SEC · 2026/11/4
  • Evercore ISI Group Maintains Outperform on Henry Schein, Lowers Price Target to $100
    Benzinga · 2026/11/4
  • Here's What Analysts Are Forecasting For Henry Schein, Inc. (NASDAQ:HSIC) After Its Third-Quarter Results
    Simply Wall St · 2026/11/6
  • Rating change
    Henry Schein Price Target Cut to $92.00/Share From $96.00 by Leerink Partners
    Dow Jones · 2026/10/15
  • Rating change
    Henry Schein Is Maintained at Neutral by UBS
    Dow Jones · 2026/11/5
  • Rating change
    Henry Schein Is Maintained at Outperform by Evercore ISI Group
    Dow Jones · 2026/11/4
  • Company notice
    Henry Schein | 8-K: Current report
    SEC · 2026/11/3
  • UBS Adjusts Henry Schein Price Target to $95 From $94, Maintains Neutral Rating
    MT Newswires · 2026/11/4
  • Barclays Maintains Henry Schein(HSIC.US) With Buy Rating, Maintains Target Price $100
    Market Newswire · 2026/11/4
  • Company notice
    Henry Schein | 8-K: Current report
    SEC · 2026/10/8
  • Rating change
    Henry Schein Is Maintained at Market Perform by Leerink Partners
    Dow Jones · 2026/10/15
  • Rating change
    Analysts Offer Insights on Healthcare Companies: Henry Schein (HSIC), Pharvaris (PHVS) and Tenet Healthcare (THC)
    TipRanks · 2026/10/12
  • Company notice
    Henry Schein | 8-K: Current report
    SEC · 2026/9/22
  • Company notice
    Henry Schein | 4: Statement of changes in beneficial ownership of securities-Officer Albertini Andrea
    SEC · 2026/9/10
  • Rating change
    Morgan Stanley Maintains Henry Schein(HSIC.US) With Sell Rating, Maintains Target Price $64
    Market Newswire · 2026/10/12
  • Company notice
    Henry Schein | SCHEDULE 13G: Others
    SEC · 2026/8/6

Headlines are aggregated automatically and are not independently verified or edited by our team.

Quote time 2026-11-20 20:01:08 · For reference only, not investment advice and not tailored to your situation.

Henry Schein discussion 0 comments

Add a comment